Age and frailty in anticancer drug regulatory assessment: a comprehensive cohort study of European marketing authorisations 2012-2023
Background: Prevalence of cancer increases with age, but older adults remain underrepresented in pivotal clinical trials. We analysed the representation of older adults and poor performance score patients in initial marketing authorisation (MA) of new anticancer medicines in the European Union (EU)....
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2026-03-01
|
| Edice: | ESMO Real World Data and Digital Oncology |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2949820125005521 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|